TP53 and breast cancer: Furthermore, stratified analysis of clinicopathologic features revealed that BC patients in the high-risk group had a significantly shorter OS period in several strata, such as ER status (ER− or ER+) (Figs. 5A and 5B), PR status (PR− or PR+) (Figs. 5C and 5D), HER2 status (HER2− or HER2+) (Figs. 5E and 5F), TNBC (non-TNBC or TNBC) (Figs. 5G and 5H), and P53 status (P53 mutated type or P53 wild-type) (Fig. 5I and 5J).